BAGUERA® C in the US – Investigational Device Exemption (IDE) FDA Approval 2 levels

Following the recent FDA approval to initiate a pivotal IDE clinical study for the BAGUERA® C artificial cervical disc at 1-level, Spineart is proud to announce that it has received approval from the FDA to initiate as well a pivotal IDE clinical study for BAGUERA® C at two contiguous levels.
Both studies will be randomized controlled trials comparing the BAGUERA® C artificial cervical disc to another FDA approved arthroplasty device and they will take place simultaneously at up to 30 centers across the country.

 

BAGUERA® C Cervical Disc Prosthesis

The BAGUERA® C Cervical Disc Prosthesis is an MRI compatible disc. The endplates of the BAGUERA® C are anatomically shaped and the inner layers are coated with a diamond-like material that features a low coefficient of friction. The load sharing design and the guided mobile nucleus are intended to prevent excessive constraints on the facet joints and adjacent levels

Caution ­Investigational Device, Limited by Federal (or United States) Law to Investigational Use

Related

Related items
Date - Category Illustration Title Excerpt
  • Corporate
26 September 2025 Plan-Les-Ouates & Zurich (CH) – Antwerp (BE) Spineart (www.spineart.com), a global medtech innovator in advanced spine surgery solutions, today announces a CHF 25 million capital increase backed...
  • Product
Spineart announces the full-market launch of its SCARLET® AC-Ti secured anterior cervical cage in the United States. Following 510(k) clearance in May 2024, SCARLET® AC-Ti has been extensively evaluated by...
  • BAGUERA® C
Spineart today announces that it has completed a planned interim analysis for its 2-level BAGUERA® C IDE study, which showed that BAGUERA® C, its innovative cervical disc prosthesis, met the...